FEEDS
Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
Paris (ots/PRNewswire) - - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
European Commission Approves Labelling Update for REYATAZ® (atazanavir sulfate) in Pregnant Women Living With HIV
Paris, November 25 (ots/PRNewswire) - - REYATAZ(R) is the only boosted PI to include dosing and medical guidance in pregnancy and postpartum in the label - Bristol-Myers Squibb Company today announced that the European ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
YERVOY(TM) (ipilimumab) Approved for the Treatment of Previously-Treated Advanced Melanoma in the EU
Paris (ots/PRNewswire) - - First and Only Approved Therapy for Pre-treated Unresectable or Metastatic Melanoma to Demonstrate a Significant Improvement in Overall Survival - First EU-Approved Therapy for ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
www.aktiv-mit-rheuma.de / Viele Tipps und breites Serviceangebot für Rheuma-Patienten jetzt online
München (ots) - Der Alltag für Patienten mit Rheumatoider Arthritis ist häufig geprägt durch Schmerzen und einer Einschränkung der Lebensqualität. Auf www.aktiv-mit-rheuma.de bietet das forschende pharmazeutische Unternehmen Bristol-Myers Squibb ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
First-in-class Biologic Agent for Kidney Transplant Rejection Approved in Europe
Paris (ots/PRNewswire) - - European Commission approves NULOJIX(R) (belatacept), in combination with corticosteroids and a mycophenolic acid and an interleukin-2 receptor antagonist at induction, for prophylaxis of graft ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Five-Year Follow-Up Data for SPRYCEL(R) (dasatinib) 100 mg Once Daily Demonstrated 78 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib Mesylate[*]
Paris (ots/PRNewswire) - Five-year follow-up results were presented today from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Second Phase 3 Study of YERVOY(TM) (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Princeton, New Jersey (ots/PRNewswire) - - Study 024 Evaluated Newly-Diagnosed Patients Treated with YERVOY at Investigational Dose of 10mg/kg in Combination with Dacarbazine vs. Dacarbazine Alone - Forty-Seven Percent of Patients Treated with ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Bristol-Myers Squibb Receives CHMP Positive Opinion for YERVOY(TM) (ipilimumab) for Previously-Treated Patients With Metastatic Melanoma
Paris (ots/PRNewswire) - YERVOY (ipilimumab) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with previously-treated unresectable or metastatic melanoma. The European ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
BARACLUDE(R) (entecavir) Approved by the European Commission for the Treatment of Chronic Hepatitis B in Adult Patients With Evidence of Decompensated Liver Disease
Paris (ots/PRNewswire) - Bristol-Myers Squibb announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
European Approval for SPRYCEL(R) (dasatinib) in Adult Patients With Newly Diagnosed CML: First New Approved Treatment in the E.U. With Superior Efficacy vs. Imatinib Since 2001
Paris (ots/PRNewswire) - Bristol-Myers Squibb today announced that SPRYCEL(R) (dasatinib) 100mg once daily received Marketing Authorization from the European Commission for the treatment of adult patients with newly diagnosed Philadelphia chromosome ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Follow-Up Results from Study Comparing SPRYCEL(R) (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data[1]
Princeton, New Jersey and Tokyo (ots/PRNewswire) - Bristol-Myers Squibb Company (http://www.bms.com) and Otsuka Pharmaceutical Co., Ltd. today announced 18-month follow-up results from the Phase 3 DASISION study of SPRYCEL(R) (dasatinib) 100 mg ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
SPRYCEL(R) (dasatinib) Receives CHMP Positive Opinion for the Treatment of Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia in Chronic Phase
Paris (ots/PRNewswire) - Bristol-Myers Squibb today announced that SPRYCEL(r) (dasatinib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with newly diagnosed ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Women with HIV: A Growing Challenge
Cologne, Germany, November 12 (ots/PRNewswire) - - With Women Comprising Over Half of the Global HIV/AIDS Population,(1) Leading Experts to Convene to Explore the Impact of Gender on Treatment and Care With 33 million individuals infected, HIV/AIDS ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
New Data on Four Bristol-Myers Squibb Compounds to be Presented at AASLD 2009
Princeton, New Jersey (ots/PRNewswire) - New data on four Bristol-Myers Squibb Company (NYSE: BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Leading HIV Experts Convene to Tackle the Challenge of Late Presentation in Europe
London (ots/PRNewswire) - - Between 15 to 38 percent of HIV-infected persons in Europe do not present for screening and treatment until late in infection.(1) Late presentation has been show to result in increased morbidity(1) and decreasing ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Europäische Kommission erteilt Zulassung für REYATAZ(R) (Atazanavirsulfat 100 mg, 150 mg, 200 mg, 300 mg) in Kombination mit anderen antiretroviralen Arzneimitteln für HIV-1-infizierte Erwachsene, die zuvor noch nicht behandelt worden waren
Paris (ots/PRNewswire) - - REYATAZ(R), zusammen mit Ritonavir verabreicht, eröffnet bisher noch nicht behandelten HIV-1-infizierten Erwachsenen in der Europäischen Union zusätzliche Therapieoptionen Die Europäische Kommission hat die Zulassung für ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Neue Therapieoption ermöglicht verbesserte Lebensqualität bei Rheumatoider Arthritis
München (ots) - Der diesjährige Weltrheumatag thematisiert die Einschränkungen von Menschen mit Rheumatoider Arthritis (RA). Alltägliche Situationen, wie die Schuhe zu binden oder eine Flasche Wasser zu öffnen, können aufgrund der ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
Ein Virus als "global player" / Die chronische Infektion mit Hepatitis B: Häufig zu spät erkannt / Welt-Hepatitis-Tag am 1. Oktober
Bristol-Myers Squibb bietet mit dem Programm SECURE THE FUTURE(R) neuen Ansatz, um erfolgreiches Modell zur Behandlung von HIV zu wiederholen
Sydney, Australien (ots/PRNewswire) - Bristol-Myers Squibb hat heute angekündigt, mit einem neuen Ansatz sein Programm SECURE THE FUTURE(R) in den Entwicklungsländern auszuweiten, indem es seine bislang erfolgreichsten Unterstützungsprogramme ... weiter zur Pressemitteilung von Bristol-Myers Squibb GmbH & Co.KG aA
